Developer docs
API playgroundTry for free, no card

Search company profiles

NEOGAP Therapeutics

Full company profile

uuid0000hd6

Namestring
NEOGAP Therapeutics
Legal namestring
Neogap Therapeutics AB
Websiteurl
neogap.se
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
personalised cancer immunotherapy, cell-based immunotherapy, neoantigen targeting therapy, T cell expansion technology, immuno-oncology therapeutics
Industry2 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Personalised Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Cell therapy product commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company developing personalised cancer immunotherapy. Revenue expected from eventual commercialisation of pTTL therapy following clinical development and regulatory approval, with potential out-licensing to pharmaceutical partners.

neogap.se
2Technology licensing
TypeLicensing Royalties
Description

EpiTCer technology platform applicable beyond cancer to autoimmune diseases, potentially licensable to pharmaceutical and biotech companies

neogap.se
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NEOGAP Therapeutics develops personalised cancer cell-based immunotherapy (pTTL) using a patient's own T cells, supported by two proprietary platforms: PIOR®, a machine-learning software that identifies and ranks up to 36 tumour-specific neoantigens per patient, and EpiTCer®, a patented bead-based technology that expands and trains those T cells to target the identified neoantigens. The lead clinical programme targets advanced/metastatic colorectal cancer and is currently in a Phase I/II trial at Swedish hospitals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Positive safety profile: no serious treatment-related adverse events observed in initial trial data
+3 more records
Product overview1 text field

NEOGAP Therapeutics offers a unified personalised cancer immunotherapy platform consisting of three integrated components: pTTL (Personalised Tumour Trained Lymphocytes) as the core therapy product, PIOR® software for neoantigen identification and selection using machine learning, and EpiTCer® technology for T cell expansion and training. The platform uses the patient's own cells from tumour-draining lymph nodes to create a tailor-made treatment targeting patient-specific neoantigens, with initial focus on advanced colorectal cancer.

Product and service3 records
1pTTL (personalised Tumour Trained Lymphocytes)
CategoryCell-based personalised immunotherapy
Description

A personalised cell-based immunotherapy that enhances the patient's own T cells from tumour-draining lymph nodes to fight cancer by training them to target patient-specific tumour neoantigens. Initially focused on advanced/metastatic colorectal cancer, with potential application across solid tumour types. Currently in Phase I/II clinical trial.

2PIOR® (Personalised Immuno-Oncology Ranking)
CategoryNeoantigen identification software
Description

A proprietary machine-learning software platform that uses DNA and RNA next-generation sequencing data from tumour and healthy tissue to identify, select, and rank up to 36 tumour-specific neoantigens per patient. PIOR is a foundational component of the pTTL therapy workflow and is GDPR-compliant.

3EpiTCer® Technology
CategoryT cell expansion and training technology
Description

A patented technology platform using superparamagnetic microbeads coupled with personalised neoantigens that are taken up by antigen-presenting cells, which then activate and expand tumour-targeting T cells. Used to expand and train patient T cells for the pTTL therapy, with additional applications in detecting antigen-specific autoreactive T cells in autoimmune disease research.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Vinnova-funded (SEK 1M) collaboration to explore pathways for US clinical studies. Combines Neogap's clinical expertise with Weill Cornell's TIL therapy and translational immuno-oncology experience, preparing for potential Phase II US sites.

2NorthX Biologics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Strategic collaboration with leading CDMO to advance manufacturing strategies for personalised cancer cell therapy. Partnership aims to optimise and scale production for future clinical trials and commercialisation through GMP process industrialisation.

neogap.se
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-25
Description

French biotech collaboration under Eurostars funding (SEK 5M) to develop analysis method for T cell activity against tumours. Okomera contributes organoid screening technology and killing assay methodology to predict therapy efficacy.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-05-04
Description

Zurich-based company using Neogap's EpiTCer technology in Phase II study for multiple sclerosis therapy RED4MS. Neogap provides technology for detecting autoreactive T cells as biomarkers.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Swedish CRO contracted for first clinical trial in colorectal cancer, providing clinical trial management services.

6CDMO NorthX Biologics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Manufacturing framework development to support later-stage clinical trials and future commercialisation as part of EIC grant collaboration.

neogap.se
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

London-based clinical-stage biotech developing personalized neoantigen TIL therapies (cNeT) using DNA sequencing to identify tumor-specific clonal neoantigens and expand tumor-infiltrating lymphocytes. Extremely close mechanistic analog to Neogap's pTTL approach (both use patient T cells + neoantigen targeting without genetic modification) and is in Phase I/II for NSCLC and melanoma.

TypeDirect peer
Description

US clinical and commercial-stage cell therapy company developing autologous TIL therapies for solid tumors. FDA-approved lifileucel (Amtagvi) for advanced melanoma and ongoing trials in cervical cancer and other indications. Most commercially advanced direct competitor in TIL therapy space.

TypeDirect peer
Description

Clinical-stage cell therapy company developing engineered TCR-T cell therapies (SPEAR T-cells) targeting solid tumor antigens including neoantigens. FDA-approved Tecelra for synovial sarcoma. Comparable in mechanism (T cell receptor-mediated targeting of tumor antigens) and clinical-stage T cell therapy execution.

TypeDirect peer
Description

German clinical-stage biotech developing TCR-based immunotherapies (ACTengine, ACTallo) and bispecifics (TCER) targeting tumor-specific peptides including neoantigens. Very close peer on the neoantigen identification and TCR-T cell therapy axis, with multiple clinical programs and Big Pharma partnerships.

TypeDirect peer
Description

US clinical-stage cell therapy company developing autologous TIL therapies (ITIL-306 and others) for solid tumors including melanoma, cervical, and lung cancers. Direct TIL therapy peer with comparable clinical-stage positioning and manufacturing approach.

6Turnstone Biologics
TypeDirect peer
Description

Clinical-stage biotech developing next-generation tumor-infiltrating lymphocyte (TIL) therapies with selected TIL (Selected TIL) and viral immunotherapy platforms for solid tumors. Direct mechanistic peer to Neogap's pTTL in TIL therapy space.

TypeDirect peer
Description

US clinical-stage cell therapy company developing multi-tumor-associated antigen (MultiTAA)-specific T cell therapies for solid tumors and hematologic malignancies. Smaller emerging peer using non-engineered, antigen-specific T cell approaches for solid tumors.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Global pharmaceutical leader with approved CAR-T cell therapies (Breyanzi, Abecma) and a broad immuno-oncology portfolio including checkpoint inhibitors. Key potential out-licensing partner and broad competitive incumbent in cell therapy and oncology.

TypeBroad incumbent
Description

German biotech with multiple personalized neoantigen programs including FixVac (off-the-shelf mRNA cancer vaccines), individualized mRNA vaccines (BNT122 in Phase II with Genentech), and CAR-T programs (BNT211). Broad incumbent in personalized cancer immunotherapy and likely strategic partner/acquirer for Neogap.

TypeBroad incumbent
Description

US biotech with mRNA-4157 individualized neoantigen cancer vaccine in Phase III (KEYNOTE-942 partnership with Merck). Adjacent platform competing for the same personalized neoantigen immunotherapy value pool as Neogap's PIOR + EpiTCer platform, though via a different modality (mRNA vaccine vs. cell therapy).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NEOGAP Therapeutics

Personalised Cancer Immunotherapyneogap.se

NEOGAP Therapeutics firmographics

Firmographics
Name
NEOGAP Therapeutics
Legal name
Neogap Therapeutics AB
Website
https://neogap.se
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

NEOGAP Therapeutics industry classification

Industry
Product category
Personalised Cancer Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Personalised cancer immunotherapy
  • Cell-based immunotherapy
  • Neoantigen targeting therapy
  • T cell expansion technology
  • Immuno-oncology therapeutics

Where NEOGAP Therapeutics is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

NEOGAP Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Cell therapy product commercialization: Pre-revenue clinical-stage company developing personalised cancer immunotherapy. Revenue expected from eventual commercialisation of pTTL therapy following clinical development and regulatory approval, with potential out-licensing to pharmaceutical partners.
  2. Technology licensing: EpiTCer technology platform applicable beyond cancer to autoimmune diseases, potentially licensable to pharmaceutical and biotech companies

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

NEOGAP Therapeutics product offering

Product offering

Core offering

NEOGAP Therapeutics develops personalised cancer cell-based immunotherapy (pTTL) using a patient's own T cells, supported by two proprietary platforms: PIOR®, a machine-learning software that identifies and ranks up to 36 tumour-specific neoantigens per patient, and EpiTCer®, a patented bead-based technology that expands and trains those T cells to target the identified neoantigens. The lead clinical programme targets advanced/metastatic colorectal cancer and is currently in a Phase I/II trial at Swedish hospitals.

Product overview

NEOGAP Therapeutics offers a unified personalised cancer immunotherapy platform consisting of three integrated components: pTTL (Personalised Tumour Trained Lymphocytes) as the core therapy product, PIOR® software for neoantigen identification and selection using machine learning, and EpiTCer® technology for T cell expansion and training. The platform uses the patient's own cells from tumour-draining lymph nodes to create a tailor-made treatment targeting patient-specific neoantigens, with initial focus on advanced colorectal cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • pTTL (personalised Tumour Trained Lymphocytes) A personalised cell-based immunotherapy that enhances the patient's own T cells from tumour-draining lymph nodes to fight cancer by training them to target patient-specific tumour neoantigens. Initially focused on advanced/metastatic colorectal cancer, with potential application across solid tumour types. Currently in Phase I/II clinical trial.
  • PIOR® (Personalised Immuno-Oncology Ranking) A proprietary machine-learning software platform that uses DNA and RNA next-generation sequencing data from tumour and healthy tissue to identify, select, and rank up to 36 tumour-specific neoantigens per patient. PIOR is a foundational component of the pTTL therapy workflow and is GDPR-compliant.
  • EpiTCer® Technology A patented technology platform using superparamagnetic microbeads coupled with personalised neoantigens that are taken up by antigen-presenting cells, which then activate and expand tumour-targeting T cells. Used to expand and train patient T cells for the pTTL therapy, with additional applications in detecting antigen-specific autoreactive T cells in autoimmune disease research.

Quantifiable outcome

  • Positive safety profile: no serious treatment-related adverse events observed in initial trial data
  • +3 more outcomes

Companies that use NEOGAP Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

NEOGAP Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

NEOGAP Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major, core and minor.

  • Weill Cornell MedicinemajorStrategic or Co-development Partner · 5 November 2025Vinnova-funded (SEK 1M) collaboration to explore pathways for US clinical studies. Combines Neogap's clinical expertise with Weill Cornell's TIL therapy and translational immuno-oncology experience, preparing for potential Phase II US sites.
  • NorthX BiologicscoreStrategic or Co-development Partner · 4 November 2024Strategic collaboration with leading CDMO to advance manufacturing strategies for personalised cancer cell therapy. Partnership aims to optimise and scale production for future clinical trials and commercialisation through GMP process industrialisation.
  • OkomeraminorStrategic or Co-development Partner · 25 March 2024French biotech collaboration under Eurostars funding (SEK 5M) to develop analysis method for T cell activity against tumours. Okomera contributes organoid screening technology and killing assay methodology to predict therapy efficacy.
  • CellerysminorStrategic or Co-development Partner · 4 May 2023Zurich-based company using Neogap's EpiTCer technology in Phase II study for multiple sclerosis therapy RED4MS. Neogap provides technology for detecting autoreactive T cells as biomarkers.
  • Clinical Trial Consultants AB (CTC)minorImplementation/ SI/ Consulting PartnerSwedish CRO contracted for first clinical trial in colorectal cancer, providing clinical trial management services.
  • CDMO NorthX BiologicscoreStrategic or Co-development PartnerManufacturing framework development to support later-stage clinical trials and future commercialisation as part of EIC grant collaboration.

Scale indicators6 records

Recent moves2 records

Expansion highlights6 records

NEOGAP Therapeutics competitors and assessment

Company assessment

Direct peers

  • Achilles Therapeutics: London-based clinical-stage biotech developing personalized neoantigen TIL therapies (cNeT) using DNA sequencing to identify tumor-specific clonal neoantigens and expand tumor-infiltrating lymphocytes. Extremely close mechanistic analog to Neogap's pTTL approach (both use patient T cells + neoantigen targeting without genetic modification) and is in Phase I/II for NSCLC and melanoma.
  • Iovance Biotherapeutics: US clinical and commercial-stage cell therapy company developing autologous TIL therapies for solid tumors. FDA-approved lifileucel (Amtagvi) for advanced melanoma and ongoing trials in cervical cancer and other indications. Most commercially advanced direct competitor in TIL therapy space.
  • Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T cell therapies (SPEAR T-cells) targeting solid tumor antigens including neoantigens. FDA-approved Tecelra for synovial sarcoma. Comparable in mechanism (T cell receptor-mediated targeting of tumor antigens) and clinical-stage T cell therapy execution.
  • Immatics: German clinical-stage biotech developing TCR-based immunotherapies (ACTengine, ACTallo) and bispecifics (TCER) targeting tumor-specific peptides including neoantigens. Very close peer on the neoantigen identification and TCR-T cell therapy axis, with multiple clinical programs and Big Pharma partnerships.
  • Instil Bio: US clinical-stage cell therapy company developing autologous TIL therapies (ITIL-306 and others) for solid tumors including melanoma, cervical, and lung cancers. Direct TIL therapy peer with comparable clinical-stage positioning and manufacturing approach.
  • Turnstone Biologics: Clinical-stage biotech developing next-generation tumor-infiltrating lymphocyte (TIL) therapies with selected TIL (Selected TIL) and viral immunotherapy platforms for solid tumors. Direct mechanistic peer to Neogap's pTTL in TIL therapy space.
  • Marker Therapeutics: US clinical-stage cell therapy company developing multi-tumor-associated antigen (MultiTAA)-specific T cell therapies for solid tumors and hematologic malignancies. Smaller emerging peer using non-engineered, antigen-specific T cell approaches for solid tumors.

Broad incumbents

  • Bristol-Myers Squibb: Global pharmaceutical leader with approved CAR-T cell therapies (Breyanzi, Abecma) and a broad immuno-oncology portfolio including checkpoint inhibitors. Key potential out-licensing partner and broad competitive incumbent in cell therapy and oncology.
  • BioNTech: German biotech with multiple personalized neoantigen programs including FixVac (off-the-shelf mRNA cancer vaccines), individualized mRNA vaccines (BNT122 in Phase II with Genentech), and CAR-T programs (BNT211). Broad incumbent in personalized cancer immunotherapy and likely strategic partner/acquirer for Neogap.
  • Moderna: US biotech with mRNA-4157 individualized neoantigen cancer vaccine in Phase III (KEYNOTE-942 partnership with Merck). Adjacent platform competing for the same personalized neoantigen immunotherapy value pool as Neogap's PIOR + EpiTCer platform, though via a different modality (mRNA vaccine vs. cell therapy).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NEOGAP Therapeutics social profiles

Digital presence

NEOGAP Therapeutics compliance and trust

Trust signal

Compliance1 record

NEOGAP Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NEOGAP Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

NEOGAP Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NEOGAP Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NEOGAP Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEOGAP Therapeutics

What does NEOGAP Therapeutics do?

NEOGAP Therapeutics develops personalised cancer cell-based immunotherapy (pTTL) using a patient's own T cells, supported by two proprietary platforms: PIOR®, a machine-learning software that identifies and ranks up to 36 tumour-specific neoantigens per patient, and EpiTCer®, a patented bead-based technology that expands and trains those T cells to target the identified neoantigens. The lead clinical programme targets advanced/metastatic colorectal cancer and is currently in a Phase I/II trial at Swedish hospitals.

Is NEOGAP Therapeutics a public or private company?

NEOGAP Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was NEOGAP Therapeutics founded?

NEOGAP Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is NEOGAP Therapeutics based?

NEOGAP Therapeutics is headquartered in Stockholm, Sweden, in the Europe region.

How does NEOGAP Therapeutics make money?

Two revenue lines are on record. Cell therapy product commercialization is the primary driver. The others are technology licensing.

Who are NEOGAP Therapeutics's main competitors?

Direct peers on record are Achilles Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immatics, Instil Bio, Turnstone Biologics and Marker Therapeutics. Broad incumbents are Bristol-Myers Squibb, BioNTech and Moderna.

Does NEOGAP Therapeutics have an API?

No public API is recorded for NEOGAP Therapeutics.

What industry is NEOGAP Therapeutics in?

NEOGAP Therapeutics's product category is Personalised Cancer Immunotherapy. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NeogapNeogap secures SEK 87 million to advance clinical development of its personalised immunotherapy – NEOGAPSwedish biotechnology company Neogap Therapeutics has raised SEK 87 million in a financing round led by Sciety to advance its ongoing first-in-human clinical trial of personalised cell therapy for advanced colorectal cancer. The funding will support the continuation of the trial, which has shown that the treatment is well tolerated, and enable preparations for the next stage of clinical development. Neogap has also received approval from the Swedish Medical Products Agency to treat all patients in the study at full dose.news.cision.comSciety leads SEK 87 million financing round in Neogap TherapeuticsSciety led a SEK 87 million financing round for Neogap Therapeutics, a Swedish biotech company developing personalized cancer immunotherapy, to support ongoing clinical trials and future commercialization. The company's therapy, pTTL, has shown positive safety results and is being tested in a colorectal cancer trial in Sweden. The funding aims to advance clinical development and scale manufacturing capabilities, driven by significant market potential.The Pharma LetterNeogap capital raise for clinical development of personalized immunotherapySwedish biotech Neogap Therapeutics has raised 87 million Swedish kronor ($9.8 million) in a financing round led by Nordic investment company Sciety. The funds will support clinical development of personalized cancer immunotherapy using the patient's own cells. This represents a significant capital injection for the company's pipeline advancement.ScietySciety leads SEK 87 million financing round in Neogap TherapeuticsSciety led a SEK 87 million financing round for Neogap Therapeutics, a Swedish clinical-stage biotech company developing personalised immunotherapy for cancer. The capital will fund the company's ongoing Phase I/II clinical trial evaluating pTTL therapy for colorectal cancer and support data collection for the next development stage. Neogap has achieved key milestones including treating first patients, presenting positive initial safety data, and receiving approval to administer full doses to all trial participants.NeogapNeogap secures Eurostars funding to develop T-cell activity analysis – NEOGAPSwedish biotech Neogap Therapeutics has secured SEK 5 million in Eurostars funding to collaborate with French company Okomera on developing an analysis method for T-cell activity against tumors. This partnership aims to enhance the assessment of Neogap's pTTL cell therapy, currently in phase I/II trials for colorectal cancer, by utilizing Okomera’s innovative killing assay technology.ArcticstartupNeogap Therapeutics from Sweden receives €7.1M funding boost for personalized cancer treatment researchNeogap Therapeutics secured €7.1 million in funding through a new share issue and an EU Innovation Council grant to support its clinical phase I/II study for personalized colorectal cancer treatment. The capital injection, involving investors Sciety and Sciety Venture Partners, aims to advance the development of the company's proprietary cell therapy algorithms.NeogapNeogap raises SEK 83 million for a clinical phase ISwedish biotechnology company Neogap Therapeutics has secured SEK 83 million in funding, comprising SEK 54 million from investors Sciety and Sciety Venture Partners, and SEK 29 million from the European Innovation Council. This capital injection will support the ongoing clinical phase I/II study of its personalized cancer immunotherapy for colorectal cancer and preparations for subsequent trials. The funding provides financial stability to advance the development of the company's proprietary PIOR® and EpiTCer® technologies.news.cision.comNeogap expands team with software expert to drive cancer immunotherapy innovationNeogap Therapeutics recruited bioinformatics expert Alejandro Fernandez Woodbridge to develop its PIOR software platform for personalized cancer immunotherapy. The platform uses machine learning to identify tumor-specific T-cell targets. The company is based in Stockholm and focuses on cell therapy.news.cision.comNeogap appoints new Chief Medical OfficerNeogap Therapeutics appointed Dr. Hanjing Xie as Chief Medical Officer, effective 21 March, to oversee clinical development and the first-in-human study. The company received CTA approval for a phase I/IIa trial of its pTTL cell therapy against colorectal cancer, expected to begin in the first half of 2023.